Helix Biopharma Corp. Announces Management and Board Changes

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced that Frank Michalargias has notified the Board of Directors of the Company of his intention to resign from the position of Chief Financial Officer, effective no later than May 15, 2022. Mr. Michalargias will be departing the Company to pursue a new employment opportunity.

2022-03-22 PR